United Therapeutics Corporation Acquires Thymmune Therapeutics

Key Terms

induced pluripotent stem cells medical

Induced pluripotent stem cells (iPSCs) are adult cells that scientists have reprogrammed to behave like embryonic stem cells, meaning they can become many different cell types. For investors, iPSCs matter because they are a flexible platform for developing new drugs, testing safety, and creating personalized therapies; think of them as blank building blocks that can be used to prototype treatments and reduce development risk before large clinical bets.

ipsc medical

Induced pluripotent stem cells (iPSCs) are ordinary adult cells that scientists have reprogrammed back into a versatile, embryonic-like state so they can become many different cell types. Think of them as factory-reset cells that can be turned into heart, nerve, or blood cells for testing drugs, modeling diseases, or developing cell therapies. For investors, iPSCs signal potential high-reward opportunities in new treatments and research tools but also carry technical, manufacturing and regulatory risks that affect commercial prospects.

congenital athymia medical

Congenital athymia is a rare condition in which a baby is born without a functioning thymus, the small organ that 'trains' immune cells to recognize and fight infections. Without that training, affected infants have little to no T‑cell immunity and face life‑threatening infections unless treated. For investors, the condition defines demand for specialized therapies, clinical trials, regulatory scrutiny, and long‑term care costs—factors that influence the commercial outlook for related drugs and procedures.

neo-thymus medical

A neo-thymus is a lab-grown or implanted version of the thymus, the organ that trains and matures immune cells called T cells; think of it as a replacement ‘boot camp’ for the immune system. For investors, neo-thymus therapies matter because they aim to restore or improve immune function in conditions like immune deficiency or after certain cancer treatments, which can create new markets, high development costs, clinical risk, and potential regulatory milestones that affect a biotech’s value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR) announced today it has acquired Thymmune Therapeutics, Inc. (Thymmune), a privately held, preclinical stage biotechnology company developing scalable, regenerative thymic cell therapies for the potential treatment of post-transplant organ tolerance, immunodeficiencies, and autoimmune diseases.

The thymus is a critical organ for the development and proper function of key parts of the immune system, including training T-cells, which are essential for fighting infections and other diseases. Thymmune has a proprietary process for converting human-induced pluripotent stem cells (iPSC) into thymic cells, which — once inside the body — mature into cell types that can restore healthy T-cell function.

Thymmune’s lead candidate, THY-100, is in preclinical development for congenital athymia, an ultra-rare and life-threatening condition in which infants are born without a functional thymus. Animal studies have shown that treatment with THY-100 results in the in vivo formation of a neo-thymus that is capable of facilitating T-cell development. The clinical proof of concept and further development of THY-100 has the potential to broaden thymic regenerative medicine approaches for transplant tolerance, serious immune-mediated diseases, and enhanced longevity for older adults with diminished T-cell function.

“Thymmune’s platform complements United Therapeutics’ broader mission to expand the supply of transplantable organs, building on our UThymoKidney™ clinical development program and our growing strength in immunomodulatory therapeutics,” said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. “By restoring or modulating T-cell receptor diversity, Thymmune’s technology could make fundamental contributions to human health care and potentially resolve the root causes of dozens of life-threatening diseases.”

“Thymmune was founded to harness the biology of the thymus to restore immune function for patients with serious immune-mediated diseases,” said Stan Wang, M.D., Ph.D., Chief Executive Officer and Founder of Thymmune Therapeutics. “United Therapeutics shares our conviction that regenerative medicine can transform the lives of patients, and we believe its leadership in organ alternatives and cell-based technologies makes it the ideal partner to advance our platform toward broad clinical impact.”

Under the terms of the agreement, United Therapeutics acquired Thymmune for $140 million in cash, subject to certain post-closing adjustments, plus potential earn-out payments to former Thymmune equityholders of up to $160 million based upon the achievement of certain clinical and regulatory milestones by the end of 2031.

About United Therapeutics

Founded by CEO Martine Rothblatt to discover a cure for her daughter's life-threatening rare disease, pulmonary arterial hypertension, United Therapeutics transforms the treatment of rare diseases and pioneers alternatives to expand the supply of transplantable organs. From our innovative therapies to our groundbreaking manufactured organs, we are bold and unconventional. We move quickly from scientific theory to practical technologies that can save lives. As a public benefit corporation, even our legal structure reflects our commitments. We serve patients, act with integrity, create long-term shareholder value, and operate with sustainable practices that protect the future we are working to build. Visit us at www.unither.com and follow us on LinkedIn, Facebook, and Instagram.

Forward-Looking Statements

Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements regarding our plans to develop THY-100 and other products based on Thymmune’s technology, including the potential to broaden thymic regenerative medicine approaches for transplant tolerance, serious immune-mediated diseases, and enhanced longevity for older adults with diminished T-cell function, the potential for Thymmune’s technology to support our organ manufacturing programs, the potential for Thymmune’s technology to make fundamental contributions to human health care and potentially resolve the root causes of dozens of life-threatening diseases, the potential earn-out payments to the former Thymmune stockholders, our goals of expanding the supply of transplantable organs, developing practical technologies that can save lives, creating long-term shareholder value, and operating with sustainable practices. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language, and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of July 2, 2026, and assume no obligation to update or revise the information contained in this press release whether because of new information, future events, or any other reason.

UTHYMOKIDNEY is a trademark of United Therapeutics Corporation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260702920280/en/

For Further Information Contact:
Investor Inquiries
https://ir.unither.com/contact-ir

Media Inquiries
communications@unither.com

Source: United Therapeutics Corporation